Adaptive Biotech’s ClonoSeq Gets Expanded Medicare Coverage For B-Cell Lymphoma

Adaptive Biotechnologies said Thursday that Medicare contractor Palmetto GBA has expanded coverage of the company’s ClonoSeq assay to include minimal residual disease monitoring in patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.

DLBCL joins several other disease settings where ClonoSeq — a next-generation sequencing assay that assesses the clonal landscape of circulating blood cells — is already covered by Medicare, including multiple myeloma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia.

Adaptive said the coverage determination is also the first for ClonoSeq to include the assessment of MRD based on circulating tumor DNA. In DLBCL, ctDNA aids the identification of patients at high risk for recurrence and provides oncologists with information to create a more precise, personalized treatment plan.